JP2022548043A5 - - Google Patents
Info
- Publication number
- JP2022548043A5 JP2022548043A5 JP2022516107A JP2022516107A JP2022548043A5 JP 2022548043 A5 JP2022548043 A5 JP 2022548043A5 JP 2022516107 A JP2022516107 A JP 2022516107A JP 2022516107 A JP2022516107 A JP 2022516107A JP 2022548043 A5 JP2022548043 A5 JP 2022548043A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064114A JP2025118629A (ja) | 2019-09-13 | 2025-04-09 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900303P | 2019-09-13 | 2019-09-13 | |
| US62/900,303 | 2019-09-13 | ||
| PCT/CA2020/051230 WO2021046653A1 (en) | 2019-09-13 | 2020-09-11 | Anti-oncolytic virus antigen antibodies and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064114A Division JP2025118629A (ja) | 2019-09-13 | 2025-04-09 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022548043A JP2022548043A (ja) | 2022-11-16 |
| JPWO2021046653A5 JPWO2021046653A5 (https=) | 2023-09-15 |
| JP2022548043A5 true JP2022548043A5 (https=) | 2023-09-15 |
| JP7665600B2 JP7665600B2 (ja) | 2025-04-21 |
Family
ID=74867304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516107A Active JP7665600B2 (ja) | 2019-09-13 | 2020-09-11 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
| JP2025064114A Pending JP2025118629A (ja) | 2019-09-13 | 2025-04-09 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064114A Pending JP2025118629A (ja) | 2019-09-13 | 2025-04-09 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230027475A1 (https=) |
| EP (1) | EP4028417A4 (https=) |
| JP (2) | JP7665600B2 (https=) |
| KR (1) | KR20220093103A (https=) |
| CN (2) | CN118834291A (https=) |
| AU (1) | AU2020346632A1 (https=) |
| BR (1) | BR112022004575A2 (https=) |
| CA (1) | CA3154214A1 (https=) |
| MX (1) | MX2022002855A (https=) |
| WO (1) | WO2021046653A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020361337B2 (en) * | 2019-10-02 | 2025-02-06 | Bionoxx Inc. | Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof |
| JP2024513700A (ja) * | 2021-03-17 | 2024-03-27 | アドマーレ セラピューティクス ソサイエティ | 抗ワクシニアウイルス抗原抗体並びに関連する組成物及び方法 |
| KR102419397B1 (ko) * | 2021-04-02 | 2022-07-14 | 주식회사 바이오녹스 | 항암바이러스 유래 단백질을 표적으로 하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도 |
| KR102739298B1 (ko) * | 2021-04-02 | 2024-12-06 | 주식회사 바이오녹스 | 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편 |
| US20240181058A1 (en) * | 2021-04-05 | 2024-06-06 | Bionoxx Inc. | Chimeric antigen receptor targeting oncolytic virus-derived protein, immunocyte expressing same, and uses of both |
| CA3216069A1 (en) * | 2021-04-05 | 2022-10-13 | Bionoxx Inc. | Viral vector-derived target protein for anticancer therapy and binding molecule or fragment thereof specifically binding thereto |
| KR102759386B1 (ko) * | 2022-08-11 | 2025-01-24 | 성균관대학교산학협력단 | 89Zr 표지된 항-CD25 항체를 이용한 immuno-PET |
| KR102770091B1 (ko) * | 2023-04-03 | 2025-02-24 | 주식회사 셀랩메드 | 종양 용해성 바이러스 단백질-특이적 키메릭 항원 수용체 및 이의 용도 |
| WO2024210531A1 (ko) * | 2023-04-03 | 2024-10-10 | 주식회사 셀랩메드 | 종양 용해성 바이러스 단백질-특이적 키메릭 항원 수용체 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007075914A2 (en) | 2005-12-22 | 2007-07-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies against orthopoxviruses |
| CA2661659C (en) * | 2006-08-23 | 2015-10-13 | Quercegen Pharma Llc | Smallpox monoclonal antibody |
| WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| CA2981887C (en) * | 2008-03-26 | 2019-09-03 | Epitomics, Inc. | Anti-vegf antibody |
| EA201891022A1 (ru) * | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| TWI605057B (zh) * | 2015-12-18 | 2017-11-11 | 中外製藥股份有限公司 | 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法 |
| EP3519443A4 (en) * | 2016-09-30 | 2020-06-10 | Baylor College of Medicine | CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE |
| US10442867B2 (en) * | 2017-07-31 | 2019-10-15 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
| CN111163803B (zh) * | 2017-08-11 | 2025-05-09 | 希望之城公司 | 表达car t细胞靶物的溶瘤病毒及其用途 |
| JP2024513700A (ja) * | 2021-03-17 | 2024-03-27 | アドマーレ セラピューティクス ソサイエティ | 抗ワクシニアウイルス抗原抗体並びに関連する組成物及び方法 |
-
2020
- 2020-09-11 EP EP20863181.2A patent/EP4028417A4/en active Pending
- 2020-09-11 JP JP2022516107A patent/JP7665600B2/ja active Active
- 2020-09-11 CN CN202410848156.9A patent/CN118834291A/zh active Pending
- 2020-09-11 WO PCT/CA2020/051230 patent/WO2021046653A1/en not_active Ceased
- 2020-09-11 MX MX2022002855A patent/MX2022002855A/es unknown
- 2020-09-11 KR KR1020227012100A patent/KR20220093103A/ko active Pending
- 2020-09-11 CN CN202080079310.0A patent/CN114729031B/zh active Active
- 2020-09-11 US US17/642,089 patent/US20230027475A1/en active Pending
- 2020-09-11 AU AU2020346632A patent/AU2020346632A1/en active Pending
- 2020-09-11 BR BR112022004575A patent/BR112022004575A2/pt unknown
- 2020-09-11 CA CA3154214A patent/CA3154214A1/en active Pending
-
2025
- 2025-04-09 JP JP2025064114A patent/JP2025118629A/ja active Pending